Skip to main content

Table 5 The multiple logistics regression analysis of risk factors for MACE and Bleeding

From: Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study

Variables (%) MACE (n = 101) No-MACE (n = 250) OR (95% CI) P value Bleeding (n = 18) No-Bleeding (n = 333) OR (95% CI) P value
Age > 65 23 (22.8) 66 (26.4) 0.767 (0.423–1.389) 0.381 6 (33.3) 83 (24.9) 0.660 (0.203–2.150) 0.491
BMI > 26 kg/m2 81 (80.2) 178 (71.2) 1.436 (0.795–2.595) 0.230 9 (50) 250 (75.1) 2.615 (0.779–8.781) 0.12
Smoking 33 (32.7) 108 (43.2) 0.751 (0.418–1.351) 0.340 6 (33.3) 135 (40.5) 1.218 (0.321–4.611) 0.772
Alcohol intake 65 (18.5) 14 (13.9) 0.475 (0.491- 0.766) 0.491 2 (11.1) 63 (18.9) 1.894 (0.298–12.026) 0.498
NSTEMI 26 (25.7) 30 (12.0) 0.586 (0.238–1.443) 0.245 3 (16.7) 53 (15.9) 0.298 (0.074–1.196) 0.088
Hypertension 57 (56.4) 140 (56.0) 1.147 (0.671–1.963) 0.616 9 (50) 190 (57.1) 1.164 (0.323–4.193) 0.817
Dyslipidemia 77 (76.2) 195 (78) 1.029 (0.574–1.843) 0.924 13 (72.2) 259 (77.8) 1.761 (0.582–5.323) 0.316
Concomitant medication
 β-Blocker 88 (87.1) 199 (79.6) 1.552 (0.79–3.046) 0.202 12 (66.7) 275 (82.6) 2.181 (0.648–7.337) 0.208
 ARB or ACEI 73 (72.3) 194 (77.6) 0.637 (0.351–1.155) 0.137 10 (55.6) 257 (77.2) 1.867 (0.534–6.531) 0.328
 CYP2C19*2 carriers 43 (42.6) 57 (22.8) 2.51 (1.534–4.09) < 0.001* 2 (11.1) 98 (29.4) 4.111 (0.440–37.414) 0.215
 CYP2C19*17 carriers 20 (19.8) 79 (31.6) 1.084 (0.331–3.549) 0.893 8 (44.4) 93 (27.9) 0.171 (0.012–2.360) 0.187
Metabolizer phenotype
 IMs 43 (42.6) 64 (25.6) 1.829 (0.463–7.226) 0.389 4 (22.2) 103 (30.9) 1.17 (0.158–8.652) 0.878
 PMs 7 (6.9) 5 (2.0) 3.643 (0.804–16.501) 0.094 / 12 (3.6) / /
 UMs 14 (13.9) 71 (28.4) 0.477 (0.125–1.826) 0.192 7 (38.9) 78 (23.4) 0.227 (0.012–4.262) 0.322
  1. BMI, body mass index; NSTEMI, non-ST-segment elevation myocardial infarction; ARB, angiotensin receptor blocker; ACEI, angiotensin antagonist inhibitor; MACE, major adverse cardiac events; IMs, intermediate metabolizers; PMs, poor metabolizers; UMs, ultra-metabolizers
  2. *P < 0.05, * the difference of MACE vs. No-MACE group by χ2 test at 0.05